We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-12.75%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$4.02B
AUM Growth
+$78.1M
Cap. Flow
+$805M
Cap. Flow %
20.04%
Top 10 Hldgs %
52.6%
Holding
62
New
8
Increased
9
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
MXCT icon
MaxCyte
MXCT
+$211M
2
ABSI icon
Absci
ABSI
+$150M
3
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$140M
4
PACB icon
Pacific Biosciences
PACB
+$88.6M
5
DNA icon
Ginkgo Bioworks
DNA
+$87.7M

Top Sells

Rank Stock Value
1
AMRS
Amyris Inc.
AMRS
+$49.1M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$45.3M
3
NEO icon
NeoGenomics
NEO
+$22.1M
4
FULC icon
Fulcrum Therapeutics
FULC
+$12.1M
5
CLOV icon
Clover Health Investments
CLOV
+$9.68M

Sector Composition

Rank Sector Weight
1 Healthcare 91.14%
2 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
51
Stoke Therapeutics
STOK
$1.84B
$3.05M 0.08%
120,000
– –
FHTX icon
52
Foghorn Therapeutics
FHTX
$271M
$3M 0.07%
215,000
-1,216
-0.6% -$13.5K
NAUT icon
53
Nautilus Biotechnolgy
NAUT
$129M
$1.38M 0.03%
225,000
-275,000
-55% -$2.19M
SANA icon
54
Sana Biotechnology
SANA
$885M
$1.35M 0.03%
60,000
– –
CLOV icon
55
Clover Health Investments
CLOV
$2.28B
– –
-726,511
Closed -$9.68M
FULC icon
56
Fulcrum Therapeutics
FULC
$283M
– –
-1,154,476
Closed -$12.1M
NEO icon
57
NeoGenomics
NEO
$2.04B
– –
-488,889
Closed -$22.1M
SGMO
58
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-550,000
Closed -$6.58M
AMRS
59
DELISTED
Amyris Inc.
AMRS
– –
-3,000,000
Closed -$49.1M
ZY
60
DELISTED
Zymergen Inc. Common Stock
ZY
– –
-30,000
Closed -$1.2M
TPTX
61
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-75,000
Closed -$5.85M
CNST
62
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-1,341,000
Closed -$45.3M
1 2
3

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Casdin Capital held 62 positions worth $4.02B, up 2% from $3.94B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Casdin Capital deployed $805M of net new capital in Q3 2021, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was MaxCyte: 13,971,334 shares worth $171M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was 23andMe Holding Co, an estimated $8M trimmed.

  • Casdin Capital's largest Q3 2021 buy was MaxCyte: 13,971,334 shares worth $171M.
  • Casdin Capital added most to Pacific Biosciences in Q3 2021, an estimated $88.6M increase.
  • Casdin Capital's biggest Q3 2021 reduction was 23andMe Holding Co, cutting an estimated $8M.
  • Casdin Capital fully exited Amyris Inc. in Q3 2021, selling an estimated $49.1M.
  • Casdin Capital's ten largest holdings make up 53% of its $4.02B portfolio in Q3 2021.
  • Casdin Capital opened 8 new positions and closed 8 in Q3 2021.
  • Casdin Capital's portfolio value rose 2% quarter-over-quarter to $4.02B.

Based on Casdin Capital's 13F filing for Q3 2021, filed 15 Nov 2021.